Saturday 17 October 2026
Export ANIX’s income statement to Excel — free account
ANIXA BIOSCIENCES INC
ANIX Healthcare Biotechnology
ANIXA BIOSCIENCES INC’s revenue for fiscal 2023 (year ended October 2023) was $210,000.00. In the quarter to July 2026, EPS fell 14.3% and free cash flow fell 17.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.67
0.11
−3.96%
Follow ANIX
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Older periods | |
|---|---|---|---|---|---|
| (72.57%) | (71.34%) | (67.46%) | (66.55%) |
+8 more TTM periods Free account |
|
| (63.45%) | (63.02%) | (60.39%) | (58.01%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(78.85%) | (76.07%) | (74.62%) | (78.50%) | |
Average Days of Receivables |
— | 0.00 | — | — | |
Free Cash Flow per Share |
(0.22) | (0.21) | (0.21) | (0.22) | |
Free Cash Flow |
(7.38) | (7.12) | (6.88) | (7.17) | |
| Other line items | |||||
Cash ROIC |
(27.25%) | (26.45%) | (24.53%) | (24.63%) | |
Accounts Receivable Turnover |
— | 0.00 | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.71 | 0.71 | 0.67 | 0.66 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.22) | (0.21) | (0.21) | (0.22) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates